Table 1.
Baseline patient and disease characteristics at advanced NSCLC.
| KRASwt n = 6089 | KRASm n = 4088 | P value | KRASG12A n = 291 | KRASG12C n = 1791 | KRASG12D n = 538 | KRASG12V n = 756 | KRASG13C n = 192 | KRASG13D n = 136 | KRASmother n = 384 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Age | <0.01a | |||||||||
| Median (years) | 64.0 | 63.0 | 63.0 | 62.0 | 63.5 | 63.0 | 62.0 | 63.0 | 63.0 | |
| Gender | <0.01b | |||||||||
| Female | 2140 (35.1%) | 1633 (39.9%) | 106 (36.4%) | 744 (41.5%) | 224 (41.6%) | 305 (40.3%) | 61 (31.8%) | 47 (34.6%) | 146 (37.1%) | |
| Smoking status | <0.01b | |||||||||
| Non-smoker | 831 (14.2%) | 149 (3.8%) | 13 (4.6%) | 26 (1.5%) | 44 (8.5%) | 33 (4.6%) | 3 (1.6%) | 10 (7.5%) | 20 (5.4%) | |
| Smoker | 5030 (85.8%) | 3804 (96.2%) | 269 (95.4%) | 1709 (98.5%) | 471 (91.5%) | 692 (95.4%) | 187 (98.4%) | 123 (92.5%) | 353 (94.6%) | |
| Tobacco consumption | <0.01a | |||||||||
| Median (pack-years) | 34.0 | 40.0 | ||||||||
| ECOG PS | 0.70b | |||||||||
| 0-1 | 1044 (75.4%) | 780 (74.6%) | 55 (80.9%) | 360 (74.4%) | 105 (76.6%) | 120 (75.0%) | 39 (70.9%) | 20 (64.5%) | 81 (73.6%) | |
| ≥2 | 341 (24.6%) | 265 (25.3%) | 13 (19.1%) | 124 (25.6%) | 32 (23.4%) | 40 (25.0%) | 16 (29.1%) | 11 (35.5%) | 29 (26.4%) | |
| Advanced disease modality | 0.46a | |||||||||
| De novo | 5197 (85.4%) | 3467 (84.8%) | 255 (87.6%) | 1517 (84.7%) | 445 (79.7%) | 638 (84.4%) | 171 (89.1%) | 113 (83.1%) | 328 (85.4%) | |
| Recurrent | 892 (14.6%) | 621 (15.2%) | 36 (12.4%) | 274 (15.3%) | 93 (17.3%) | 118 (15.6%) | 21 (10.9%) | 23 (16.9%) | 56 (14.6%) | |
| PD-L1 | <0.01b | |||||||||
| Negative | 262 (12.7%) | 186 (10.7%) | 12 (9.6%) | 70 (9.2%) | 22 (10.0%) | 40 (12.3%) | 9 (12.5%) | 6 (12.0%) | 27 (14.3%) | |
| 1%-49% | 1022 (49.4%) | 799 (45.8%) | 51 (40.8%) | 353 (46.3%) | 108 (49.3%) | 143 (43.9%) | 38 (52.8%) | 24 (48.0%) | 82 (43.4%) | |
| ≥50% | 786 (38.0%) | 759 (43.5%) | 62 (49.6%) | 340 (44.6%) | 89 (40.6%) | 143 (43.9%) | 25 (34.7%) | 20 (40.0%) | 80 (42.3%) | |
| Metastatic site | ||||||||||
| Brain | 1739 (30.9%) | 1247 (32.6%) | 0.11b | 83 (30.5%) | 550 (32.7%) | 164 (32.2%) | 232 (32.9%) | 63 (36.4%) | 43 (32.5%) | 112 (31.3%) |
| Leptomeningeal | 39 (0.6%) | 21 (0.4%) | 0.39b | |||||||
| Liver | 867 (15.4%) | 520 (13.6%) | 0.01b | 38 (14.0%) | 216 (12.8%) | 71 (13.9%) | 96 (13.6%) | 23 (13.3%) | 21 (15.9%) | 55 (15.4%) |
| Controlateral lung | 1432 (25.4%) | 1105 (28.9%) | <0.01b | |||||||
| Bones | 2140 (38.0%) | 1592 (41.6%) | <0.01b | 118 (43.4%) | 678 (40.3%) | 216 (42.4%) | 288 (40.9%) | 75 (43.4%) | 52 (39.4%) | 165 (46.1%) |
| Pleural effusion | 457 (8.1%) | 239 (6.2%) | <0.01b | |||||||
| Adrenal glands | 1248 (22.2%) | 883 (23.1%) | 0.30b |
ECOG PS, Eastern Cooperative Oncology performance status; NSCLC, non-small-cell lung cancer; PD-L1, programmed death-ligand 1.
a
Kruskal-Wallis rank sum test.
b
Pearson’s chi-square test.